We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Read MoreHide Full Article
Key Takeaways
GLUE jumps 45.41% after interim phase I data show strong activity of MRT-8102 across all study cohorts.
MRT-8102 delivers ~80-90% NEK7 degradation and cuts hsCRP by 85% in higher cardiovascular-risk patients.
GLUE plans full GFORCE-1 data in H1 2026, and multiple mid-stage study starts later in 2026.
Monte Rosa Therapeutics (GLUE - Free Report) jumped 45.41% following positive interim data from a phase-I study evaluating its immunology and inflammation pipeline candidate, MRT-8102. The candidate is a NEK7-directed molecular glue degrader (“MGD”), being developed for the treatment of inflammatory conditions driven by NLRP3, IL-1, and IL-6.
The phase I MRT-8102 study is a randomized, double-blind, placebo-controlled study in healthy volunteers and higher cardiovascular-risk subjects, designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamic effects, including NEK7 degradation and reductions in inflammatory markers such as C-reactive protein (“CRP”).
Over the past year, GLUE’s shares have surged 288.7% compared with the industry’s 20.5% rise.
Image Source: Zacks Investment Research
Key Points of Interim Study Results
Interim results demonstrated robust and consistent activity of MRT-8102 across all study cohorts. A total of 48 patients were enrolled in the single-dose cohorts, 40 patients in the multiple-dose cohorts, and 24 patients with higher cardiovascular-risk completed four weeks of treatment in part 3.
MRT-8102 achieved approximately 80–90% NEK7 degradation across all dose levels.
High-sensitivity CRP (hsCRP) level, a key inflammation marker, was reduced by 85% in the higher-risk group of patients after four weeks of dosing versus placebo, with nearly all patients reaching low-risk levels.
Treatment with MRT-8102 also lowered endogenous IL-6 below the cardiovascular risk threshold and strongly suppressed IL-1β secretion in patients with elevated CRP levels at baseline. In a small number of patients, the drug significantly reduced cerebrospinal fluid IL-6 levels, suggesting possible central nervous system activity.
The drug was well-tolerated and showed a favorable safety profile.
Monte Rosa’s Other Development Activities for 2026
Monte Rosa plans to report complete data from the GFORCE-1 study of MRT-8102 in patients with elevated cardiovascular risk in the first half of 2026, followed by the initiation of the phase II GFORCE-2 study in patients with atherosclerotic cardiovascular disease later in the year.
The company also expects partner Novartis to initiate multiple mid-stage studies of MRT-6160 in immune-related diseases in 2026.
Monte Rosa plans to present updated data from the ongoing phase I/II study of MRT-2359 at the ASCO Genitourinary Cancers Symposium in February 2026 and to initiate the MODeFIRe-1 phase II study of MRT-2359 in patients with solid tumors, including CRPC, later in the year.
Additionally, the company intends to submit IND applications in 2026 to the regulatory authority for next-generation NEK7-directed MGD and a CDK2 and/or cyclin E1-directed MGD, further expanding its inflammation and oncology pipeline.
Monte Rosa Therapeutics’ Zacks Rank & Other Stocks to Consider
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 51.1% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters with the negative average surprise being 20.21%.
Over the past 60 days, 2026 EPS estimates for CorMedix have risen from $2.49 to $2.88. Shares of CRMD have risen 3.3% over the past year.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, estimates for Indivior’s 2026 earnings per share have risen to $2.85 from $2.60. Indivior stock has rallied 196.8% over the past year.
Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Key Takeaways
Monte Rosa Therapeutics (GLUE - Free Report) jumped 45.41% following positive interim data from a phase-I study evaluating its immunology and inflammation pipeline candidate, MRT-8102. The candidate is a NEK7-directed molecular glue degrader (“MGD”), being developed for the treatment of inflammatory conditions driven by NLRP3, IL-1, and IL-6.
The phase I MRT-8102 study is a randomized, double-blind, placebo-controlled study in healthy volunteers and higher cardiovascular-risk subjects, designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamic effects, including NEK7 degradation and reductions in inflammatory markers such as C-reactive protein (“CRP”).
Over the past year, GLUE’s shares have surged 288.7% compared with the industry’s 20.5% rise.
Image Source: Zacks Investment Research
Key Points of Interim Study Results
Interim results demonstrated robust and consistent activity of MRT-8102 across all study cohorts. A total of 48 patients were enrolled in the single-dose cohorts, 40 patients in the multiple-dose cohorts, and 24 patients with higher cardiovascular-risk completed four weeks of treatment in part 3.
MRT-8102 achieved approximately 80–90% NEK7 degradation across all dose levels.
High-sensitivity CRP (hsCRP) level, a key inflammation marker, was reduced by 85% in the higher-risk group of patients after four weeks of dosing versus placebo, with nearly all patients reaching low-risk levels.
Treatment with MRT-8102 also lowered endogenous IL-6 below the cardiovascular risk threshold and strongly suppressed IL-1β secretion in patients with elevated CRP levels at baseline. In a small number of patients, the drug significantly reduced cerebrospinal fluid IL-6 levels, suggesting possible central nervous system activity.
The drug was well-tolerated and showed a favorable safety profile.
Monte Rosa’s Other Development Activities for 2026
Monte Rosa plans to report complete data from the GFORCE-1 study of MRT-8102 in patients with elevated cardiovascular risk in the first half of 2026, followed by the initiation of the phase II GFORCE-2 study in patients with atherosclerotic cardiovascular disease later in the year.
The company also expects partner Novartis to initiate multiple mid-stage studies of MRT-6160 in immune-related diseases in 2026.
Monte Rosa plans to present updated data from the ongoing phase I/II study of MRT-2359 at the ASCO Genitourinary Cancers Symposium in February 2026 and to initiate the MODeFIRe-1 phase II study of MRT-2359 in patients with solid tumors, including CRPC, later in the year.
Additionally, the company intends to submit IND applications in 2026 to the regulatory authority for next-generation NEK7-directed MGD and a CDK2 and/or cyclin E1-directed MGD, further expanding its inflammation and oncology pipeline.
Monte Rosa Therapeutics’ Zacks Rank & Other Stocks to Consider
GLUE currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Amicus Therapeutics (FOLD - Free Report) , CorMedix (CRMD - Free Report) , and Indivior (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 51.1% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters with the negative average surprise being 20.21%.
Over the past 60 days, 2026 EPS estimates for CorMedix have risen from $2.49 to $2.88. Shares of CRMD have risen 3.3% over the past year.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, estimates for Indivior’s 2026 earnings per share have risen to $2.85 from $2.60. Indivior stock has rallied 196.8% over the past year.
Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.